Central nervous system: general pharmacology and behavioural pharmacology
Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test,
Pharmacology Biochemistry and Behavior, 36(1), 157-161, (1990).
Comparative study of the behavioural, neurophysiological and motor effects of psychotropic drugs in the dog,
Biological Psychiatry, 27, 1264-1278, (1990).
Can piracetam protect a stabilized operant performance against the amnestic effects of chronic hypoxia treatment ?,
Bulletin of the Japanese Neurochemical Society, 29(1), 450-451, (1990).
Anxiolytic potential of a microgram dose of chlordiazepoxide in the open-field test,
European Journal of Pharmacology, 187, 547-549, (1990).
Effects of low doses of neuroleptics on temporal regulation in a differential reinforcement of response duration (DRRD) schedule in the dog,
Pharmacology, Biochemistry and Behavior, 37(4), 607-611, (1990).
Effect of chronic hypoxic treatment on retention of fixed-interval responding,
Physiology and Behavior, 49(3), 465-470, (1991).
Effects of specific dopaminergic agonists and antagonists in the open-field test,
Pharmacology, Biochemistry and Behavior, 39(2), 367-371, (1991).
Stimulant effect of the beta-carboline FG 7142 in the open-field test,
European Journal of Pharmacology, 200, 183-185, (1991).
Enhanced resistance effect of piracetam upon hypoxia-induced impaired retention of fixed-interval performance in rats,
Pharmacology Biochemistry and Behavior, 40(1), 1-6, (1991).
Comparative study of typical neuroleptics, clozapine and newly synthesised clozapine analogues: correlation between neurochemistry and behaviour,
Behavioural Pharmacology, 3(6), 567-579, (1992).
Differentiation of haloperidol and clozapine using a complex operant schedule in the dog,
Pharmacology Biochemistry and Behavior, 44(1), 181-189, (1993).
Effects of a long-interval retention on the hypoxia-induced impairment of performance in a fixed-interval schedule,
Behavioural Brain Research, 54, 199-203, (1993).
Amineptine improves the performance of dogs in a complex operant temporal regulation schedule,
Pharmacology Biochemistry and Behavior, 45(4), 897-903, (1993).
New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study,
Journal of Medicinal Chemistry, 36, 2107-2114, (1993).
Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study,
Journal of Medicinal Chemistry, 37, 519-525, (1994).
Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor,
European Journal of Pharmacology, 273, R1-R3, (1995).
New dibenzazepine derivatives with disinhibitory/anxiolytic and antidepressant potentials: behavioural study in the open-field and Porsolt's tests,
Behavioural Pharmacology, 6, 830-838, (1995).
Dibenzoazepine analogues: the electrophysiological properties of JL 3, a potential atypical antidepressant,
European Journal of Pharmacology, 310, 9-12, (1996).
Facilitatory effects of chronically administered citicoline on learning and memory processes in the dog,
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 22, 115-128, (1998).
Comparative study of pirlindole, a selective RIMA, and its two enantiomers using biochemical and behavioural techniques,
Behavioural Pharmacology, 9, 731-737, (1998).
The oxidation sensitivity could be a useful tool for the detection of the hematotoxicity potential of newly developed molecules: application to antipsychotic drugs,
Archives of Biochemistry and Biophysics, 370(1), 126-137, (1999).
Effect of JL 3, a putative antidepressant, on noradrenergic and serotonergic systems,
European Journal of Pharmacology, 386, 211-216, (1999).
Electrooxidation potential as a tool in the early screening for new safer clozapine-like analogues,
Journal of Medicinal Chemistry, 44(5), 769-776, (2001).
The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates,
Psychopharmacology, 157, 228-235 (2001).
Effects of JL 13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models with schizophrenia,
Journal of Pharmacology and Experimental Therapeutics, 298(1), 1-6 (2001).
Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats,
Neuroscience Letters, 319, 49-52 (2002).
New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D4.2,D2L) and serotonin (5-HT2A) receptors,
Journal of Medicinal Chemistry, 45, 5136-5149 (2002).
Advantageous safety profile of a dual selective alpha2C agonist/alpha2A antagonist antinociceptive agent, Fundamental & Clinical Pharmacology, 28(4), 423-438 (2014).